Acquisition Synergy RMC Pharmaceutical Solutions was acquired by Syner-G BioPharma Group in January 2023, enabling cross-sell of integrated CMC, regulatory strategy, and quality management services to RMC’s biotech and pharma clients through a broader Syner-G capabilities ladder.

Expanded Service Suite The combined entity offers process and analytical development, regulatory submission support, regulatory strategy, and quality management, presenting an opportunity to upsell end‑to‑end development programs to existing RMC customers who may require GMP compliance and regulatory filings.

Global Growth Syner-G’s global delivery and growth trajectory, including recent leadership hires and strategic mergers, signals capacity to onboard larger projects and international IND-to-NDA work, suggesting a fit for mid‑to‑late-stage programs seeking scale and compliance expertise.

Technology Enablement Adoption of cloud and AI-enabled tools (3D Intelligence, AI-augmented authoring, Veeva Vault, iCIMS, Cloudflare, and others) indicates a modern, tech-driven operating model ideal for selling enhanced data management, regulatory publishing, and accelerated submissions services.

Market Positioning With revenue in the low-to-mid single digits and a footprint aligned with large CROs like WuXi and PPD in scale, there is an opportunity to position Syner-G and RMC as a flexible, mid-market alternative for pharma and biotech clients seeking cost-effective, integrated CMC and regulatory solutions.